Background—Ranolazine has been shown to reduce myocardial ischemia and symptom
severity among selected patients with chronic angina. However, data regarding the effect of …

ContextRanolazine is a novel antianginal agent that reduces ischemia in patients with
chronic angina but has not been studied in patients with acute coronary syndromes (ACS) …

Ranolazine is a piperazine derivative believed to reduce anginal symptoms by preventing
ischemia-mediated sodium and calcium overload in myocardial cells through inhibition of …

Objective Assessment of treatment routine and outcome for ranolazine in clinical practice as
second-line treatment for stable angina pectoris (AP). Design and setting Multicenter …

Background Ranolazine, a piperazine derivative with anti‐ischemic effects, reduces the
frequency of angina and improves exercise performance in patients with chronic angina …

Background—Angina often persists or returns in populations following percutaneous
coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing …

Objectives: We aimed to evaluate the efficacy and safety of ranolazine in a larger and more
diverse group of patients with angina than previously studied. Background: Ranolazine is an …

Traditional anti-anginal agents such as β-blockers and nitrates improve symptoms of cardiac
ischemia by affecting either blood pressure or heart rates. Despite aggressive therapy, many …

Background Coronary microvascular dysfunction (CMD) is a common cause of angina and
exercise intolerance in patients without obstructive coronary artery disease. The efficacy of …

Background: Persistent angina is prevalent in women, who more often present with atypical
angina, and experience less relief from antianginal therapies. The impact of ranolazine on …